Ciclesonide: all 64 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Inhaled Ciclesonide Study in Preterm InfantsRecruitingNCT06589245Phase 1
• Inhaled Ciclesonide for Outpatients With COVID19TerminatedNCT04435795Phase 2/3Results posted
• A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 PatientsCompletedNCT04377711Phase 3Results posted
• Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in RussiaCompletedNCT02155881Phase 3Results posted
• Effect of High Dose Ciclesonide on Asthma ControlCompletedNCT01455194Phase 3Results posted
• Study To Evaluate Patient Preference, Satisfaction And Efficacy Of a Nasal Aerosol Versus an Aqueous Nasal SprayCompletedNCT01401465Phase 3Results posted
• Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled Corticosteroid (ICS)TerminatedNCT01397201Phase 2Results posted
• Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) TherapyTerminatedNCT01397162Phase 2Results posted
• Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).TerminatedNCT01396278Phase 2Results posted
• Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) AxisCompletedNCT01033825Phase 3Results posted
• Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic RhinitisCompletedNCT00790023Phase 3Results posted
• Comparison Between Systemic Exposure to Ciclesonide Nasal Spray, Ciclesonide HFA Nasal Aerosol and Orally Inhaled Ciclesonide (BY9010/M1-422)CompletedNCT00458835Phase 4Results posted
• Asthma Care With Alvesco® (Ciclesonide) in Primary Care in Adults - The ACCEPT-study (BY9010/CA-102)CompletedNCT00404547Phase 4Results posted
• Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.CompletedNCT00392288Phase 3Results posted
• A Comparative Study of Inhaled Ciclesonide Versus Placebo in Children (6-11 Years) With AsthmaCompletedNCT00384189Phase 3Results posted
• Responsiveness of Lower Airways in Adult Patients (18-60 Years) With Stable Asthma After Treatment With Ciclesonide and Fluticasone Propionate (BY9010/NL-101)CompletedNCT00306163Phase 3Results posted
• Efficacy of Ciclesonide Inhaled Once Daily Versus Other Corticosteroids Used for Treatment of Mild Asthma in Children (4 to 11 Years) (BY9010/CA-101)CompletedNCT00163293Phase 3Results posted
• Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19)Status unknownNCT04381364Phase 2
• Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for AggravationCompletedNCT04356495Phase 2/3
• A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19CompletedNCT04330586Phase 2
• The Mannitol-Asthma-Ciclesonide-StudyCompletedNCT03839433Phase 4
• Ciclesonide vs Fluticasone Nasal Sprays in Nasal PoplyposisStatus unknownNCT02665806Phase 3
• Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of Butylated Hydroxytoluene and BI 54903 XX Via Respimat® Soft MistTM Inhaler B in Healthy Male VolunteersCompletedNCT02221375Phase 1
• Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Low Dose Inhaled CorticosteroidsWithdrawnNCT01458912Phase 2
• Study on BI 54903 (Inhaled Corticosteroid) Administered Once Daily or Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Short Acting Beta-2 Agonist (SABA) Therapy AloneWithdrawnNCT01458886Phase 2
• Omnaris Versus Levocetirizine Phase 4 StudyCompletedNCT01430260Phase 4
• Olodaterol Bridging Study in AsthmaWithdrawnNCT01428622Phase 2
• Cost-effectiveness Study of Beclomethasone Versus Ciclesonide as Controller Medications in Pediatric AsthmaCompletedNCT01333800Phase 4
• Pharmacokinetics of the Fixed Dose Combination of Tiotropium Plus BI 54903 Versus the Combination of the Monoproducts of Tiotropium and BI 54903 in Healthy VolunteersCompletedNCT01309139Phase 1
• Small Particle Steroids in Refractory AsthmaCompletedNCT01171365Phase 4
• Usefulness of Exhaled Breath Condensate for Evaluation of Markers of Airway Inflammation in Children With AsthmaStatus unknownNCT00961155Phase 2
• Ciclesonide for the Treatment of Airway HyperresponsivenessCompletedNCT00826969Phase 4
• Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy (BY9010/M1-490)CompletedNCT00806754Phase 4
• To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)CompletedNCT00659841Phase 3
• To Assess the Safety and Efficacy of Ciclesonide Applied as a Nasal Spray in the Treatment of Perennial Allergic Rhinitis (BY9010/M1-402)CompletedNCT00659750Phase 3
• Study Using the Environmental Exposure Chamber (EEC) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in Treatment of Seasonal Allergic Rhinitis (BY9010/M1-406)CompletedNCT00659594Phase 3
• Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)CompletedNCT00659503Phase 3
• Investigation of Potential Additive Inhibitory Effects on HPA-Axis of Ciclesonide Nasal Spray When Administered Concomitantly With Orally Inhaled Beclomethasone Dipropionate (HFA-BDP) in Patients With Perennial Allergic Rhinitis (PAR) (BY9010/M1-408)CompletedNCT00659048Phase 3
• Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)CompletedNCT00546520Phase 3
• Effect of Ciclesonide on Exercise Induced BronchoconstrictionCompletedNCT00525772Phase 3
• A Study of Ciclesonide Nasal Spray in Patients 18 Years and Older With Seasonal Allergic Rhinitis (BY9010/M1-413)CompletedNCT00384475Phase 3
• Evaluation of Traditional Paper Symptom Diary vs. the VOCEL Mobile DiaryCompletedNCT00367263Not applicable
• Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)CompletedNCT00305487Phase 3
• Effect of Ciclesonide on Quality of Life in Patients With Moderate Persistent Asthma (21 to 65 y) (BY9010/AR-101)CompletedNCT00305461Phase 3
• Effects of Ciclesonide MDI 50mg/Day and 200mg/Day (Ex-Valve) Once-Daily on Growth in Children With Mild Persistent AsthmaCompletedNCT00270348Phase 3
• Safety and Tolerability of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis (2-5 Years Old) (BY9010/M1-416)CompletedNCT00261287Phase 3
• Effects Of Ciclesonide And Beclomethasone On Lens Opacification In Adult Subjects With Moderate To Severe Persistent AsthmaCompletedNCT00254956Phase 3
• Efficacy of Ciclesonide Versus Placebo Administered Either as Once Daily or Twice Daily in Patients Treated Previously With an Inhaled CorticosteroidCompletedNCT00174733Phase 3
• Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.CompletedNCT00174720Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Children (6 to 11 Years) With Perennial Allergic Rhinitis (BY9010/M1-403)CompletedNCT00163514Phase 3
• Safety and Effectiveness of Ciclesonide Nasal Spray in Patients With Perennial Allergic Rhinitis During One Year Treatment (BY9010/M1-404)CompletedNCT00163501Phase 3
• Safety of Ciclesonide Nasal Spray Administered With Inhaled Fluticasone Dipropionate/Salmeterol in Adults With Perennial Allergic Rhinitis (BY9010/M1-409)CompletedNCT00163488Phase 3
• Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (6 to 11 y) (BY9010/M1-206)CompletedNCT00163462Phase 3
• Efficacy and Safety of Ciclesonide in Preschool Children With Asthma (2 to 6 Years) (BY9010/M1-207)CompletedNCT00163449Phase 3
• Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)CompletedNCT00163436Phase 3
• Efficacy of Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (12 to 75 y) (BY9010/M1-142)CompletedNCT00163423Phase 3
• Efficacy of Ciclesonide Inhaled Once Daily Versus Fluticasone Propionate Inhaled Twice Daily in Children With Asthma (4 to 15 y) (BY9010/M1-205)CompletedNCT00163410Phase 3
• Efficacy of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-137)CompletedNCT00163397Phase 3
• Effectiveness of Ciclesonide Versus Budesonide in Patients With Asthma (18 to 75 y) (BY9010/M1-136)CompletedNCT00163384Phase 3
• Effects of Inhaled Ciclesonide Versus Fluticasone Propionate Versus Placebo on Lower Leg Growth in Prepubertal Children With Mild Persistent Asthma (6 to 12 y) (BY9010/M1-208)CompletedNCT00163371Phase 3
• Efficacy of Ciclesonide vs Fixed Combination of Fluticasone Propionate/Salmeterol vs Placebo in Patients With Mild Persistent Asthma (12 to 75 y) (BY9010/M1-132)CompletedNCT00163358Phase 3
• Efficacy of Ciclesonide on Small Airways in Patients With Stable Asthma (18 to 60 y) (BY9010/M1-131)CompletedNCT00163345Phase 3
• Effect of Inhaled Ciclesonide Versus Fluticasone Propionate in Patients With Mild to Moderate Asthma (18 to 65 y) (BY9010/M1-129)CompletedNCT00163332Phase 3
• Efficacy of Ciclesonide and Fluticasone Propionate in Adult Patients With Moderate and Severe Persistent Asthma (18 to 75 y) (BY9010/IT-101)CompletedNCT00163319Phase 3

← Ciclesonide overview